Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral
salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1
mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and
bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and
ovaries. This study may help doctors determine if the two surgical procedures are nearly the
same for ovarian cancer risk reduction for women with BRCA1 mutations.
-
Click here for details...
This phase II trial studies how well olaparib and cediranib maleate work in treating patients
with endometrial cancer that has come back (recurrent), does not respond to treatment
(refractory), or has spread to other places in the body (metastatic). Olaparib and cediranib
maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
-
Click here for details...
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin
works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or
peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the
body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used
in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving letrozole alone or in
combination with paclitaxel and carboplatin works better in treating patients with low-grade
serous carcinoma of the ovary or peritoneum compared to paclitaxel and carboplatin without
letrozole.
-
Click here for details...
This phase II trial studies the possible benefits of treatment with different combinations of
the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with
ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of
improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type
of treatment most patients with this condition receive if they are not part of a clinical
study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus
olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of
PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to
die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor
cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of
durvalumab, olaparib and cediranib may work better in increasing the duration of time that
the cancer does not progress compared to the usual treatment.
-
Click here for details...
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual
chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2
positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are
monoclonal antibodies and forms of targeted therapy that attach to specific molecules
(receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or
pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and
the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an
endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that
these medications will have a greater effect. Hyaluronidase also allows trastuzumab and
trastuzumab/pertuzumab to be given by injection under the skin and shortens their
administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and
in a class of medications called antimicrotubule agents. It stops cancer cells from growing
and dividing and may kill them. Carboplatin is in a class of medications known as
platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin,
but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing
the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel
and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with
HER2 positive endometrial serous carcinoma or carcinosarcoma.
|
